Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) EBITDA (2021 - 2025)

Aligos Therapeutics filings provide 5 years of EBITDA readings, the most recent being -$19.9 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 75.85% to -$19.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$24.2 million, a 81.59% increase, with the full-year FY2025 number at -$24.2 million, up 81.59% from a year prior.
  • EBITDA hit -$19.9 million in Q4 2025 for Aligos Therapeutics, up from -$31.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $43.1 million in Q1 2025 to a low of -$82.3 million in Q4 2024.
  • Median EBITDA over the past 5 years was -$22.3 million (2022), compared with a mean of -$23.3 million.
  • The widest YoY moves for EBITDA: up 223.34% in 2025, down 412.86% in 2025.
  • Aligos Therapeutics' EBITDA stood at -$37.0 million in 2021, then skyrocketed by 41.52% to -$21.6 million in 2022, then decreased by 28.65% to -$27.8 million in 2023, then plummeted by 195.49% to -$82.3 million in 2024, then surged by 75.85% to -$19.9 million in 2025.
  • The last three reported values for EBITDA were -$19.9 million (Q4 2025), -$31.5 million (Q3 2025), and -$15.9 million (Q2 2025) per Business Quant data.